ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Inhibition of biofilm formation by Limosilactobacillus fermentum supernatant against Porphyromonas gingivalis and Fusobacterium nucleatum: an in-vitro study.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aims to investigate the inhibitory effect of the supernatant of Limosilactobacillus fermentum CCFM1139 on the LuxS/AI-2 quorum sensing system in dual-species biofilms of Porphyromonas gingivalis and Fusobacterium nucleatum, and its anti-biofilm formation efficacy.
methodsConstruct an in vitro dual-species biofilm model of P. gingivalis and F. nucleatum; after adding the supernatant of L. fermentum CCFM1139 at four stages of biofilm formation (0 h, 12 h, 24 h, 36 h), the following experiments were conducted: (1) Biofilm mass changes were assessed using crystal violet staining; (2) Morphological changes were observed via scanning electron microscopy (SEM); (3) Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction(qRT-PCR) was employed to detect luxS gene expression levels in the biofilm; (4) AI-2 signaling molecule activity was quantified using Vibrio harveyi BB170 bioluminescence assay.
resultsThe supernatant of L. fermentum CCFM1139 significantly inhibited the formation of the dual-bacterial biofilm in a time-dependent manner: the inhibition rate peaked at 0 h (65.54%), followed by 60.20% at 12 h, decreasing to 47.09% at 24 h and 26.67% at 36 h. The inhibitory effect during the early phase (0-12 h) was significantly superior to that in the late phase (24-36 h) (p < 0.05). SEM observation revealed that the experimental group biofilm exhibited a loose monolayer structure with increased bacterial spacing, whereas the control group displayed a dense multilayer structure with tightly connected bacteria. qRT-PCR results indicated that the supernatant downregulated luxS gene expression in both P. gingivalis and F. nucleatum: inhibition of P. gingivalis was primarily observed between 0 and 24 h, while inhibition of F. nucleatum was stronger and more persistent. The Vibrio harveyi BB170 bioluminescence assay revealed that the supernatant from L. fermentum CCFM1139 significantly reduced the activity of the AI-2 signaling molecule in the dual-bacterial biofilm (p < 0.05).
conclusionThe supernatant of L. fermentum CCFM1139 effectively reduced biofilm formation by suppressing the LuxS/AI-2 quorum sensing system in P. gingivalis and F. nucleatum, demonstrating its potential as an antimicrobial agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.